GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

Drinking a cup or two of coffee every day may help you live longer -- but only if you skip the heavy cream and sugar, new ...

The UK's state-run health service said Thursday it will not offer two new treatments for Alzheimer's disease, citing high ...

Lilly Collaboration Accelerates RyboDyn's Dark Proteome Targets Toward First-in-Class Therapies SAN DIEGO, /PRNewswire/ -- RyboDyn, Inc., a biotechnology company pioneering first-in-class ...

A large, multicountry European study finds that adults with type 2 diabetes who start empagliflozin experience no increased ...

A huge surge in Ireland's goods exports in the first quarter of 2025 was partially due to demand for weight loss drugs in the ...

President Trump has threatened to impose pharma tariffs to encourage investment in U.S. manufacturing, but experts say there could be unintended consequences.

On the sidelines of BIO2025, Julie Gilmore, head of Lilly Gateway Labs, shares her thoughts on the $1.3 billion Verve Therapeutics buy, where Lilly’s therapeutic puck is potentially going and how the ...

Shares of Scholar Rock Holdings jumped Wednesday after the biopharmaceutical firm reported positive results from a ...

In combination with Eli Lilly’s tirzepatide, marketed as Zepbound for obesity, Scholar Rock’s monolonal antibody helped ...

Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...